NeuroSearch A/S
NeuroSearch A/S signs agreement to transfer Phase I-II projects NS2359 and NS2330 (Tesofensine)

NeuroSearch A/S 

29.10.2014 09:52

Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group
AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Company Announcement
29 October 2014


NeuroSearch A/S has signed an agreement with Saniona ApS for the transfer of
its rights to the development candidates NS2359 and NS2330 (tesofensine). 

NeuroSearch has for several years worked to raise capital for the further
development of these two development candidates, or as an alternative to enter
into agreements with third parties for the further development of the projects.
None of these have led to any result and therefore it has now been decided to
transfer the rights to NS2359 and NS2330 to Saniona. Under the agreement,
Saniona assumes the costs of maintaining the partially intertwined patent
rights to NS2359 and NS2330. NeuroSearch will not receive any cash or any other
consideration in connection with the signing of the agreement, but under the
agreement with Saniona, NeuroSearch is entitled to up to 20% of any milestones
and royalties that Saniona may obtain in connection with the further
development of NS2359 and NS2330 as well as of any potential drugs based on
NS2359 or NS2330 that may reach the market. 

Outlook for 2014
The contents of this company announcement does not affect the previously
released guidance for 2014 of an operating loss of approximately DKK 15
million. 



Contact
Allan Andersen, CEO, mobile +45 4016 3864.




About NeuroSearch
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S.
News Source: NASDAQ OMX



29.10.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      NeuroSearch A/S
              
               
              Denmark
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         DK0010224666
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------